Monsanto Third Quarter Earnings Sneak Peek

S&P 500 (NYSE:SPY) component Monsanto (NYSE:MON) will unveil its latest earnings on Wednesday, June 27, 2012. Monsanto manufactures agricultural products.

Monsanto Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for net income of $1.59 per share, a rise of 26.2% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from $1.37. Between one and three months ago, the average estimate moved down. It has risen from $1.30 during the last month. For the year, analysts are projecting profit of $3.70 per share, a rise of 25% from last year.

Past Earnings Performance: The company has beaten estimates the last four quarters and is coming off a quarter where it topped forecasts by 16 cents, reporting net income of $2.28 per share against a mean estimate of profit of $2.12 per share.

Investing Insights: Is TV the Next Bullish Catalyst for Apple’s Stock?

Wall St. Revenue Expectations: Analysts predict a rise of 11.4% in revenue from the year-earlier quarter to $4 billion.

Stock Price Performance: From May 23, 2012 to June 21, 2012, the stock price rose $5.96 (8.3%), from $71.82 to $77.78. The stock price saw one of its best stretches over the last year between December 30, 2011 and January 12, 2012, when shares rose for nine straight days, increasing 14.6% (+$10.20) over that span. It saw one of its worst periods between September 15, 2011 and September 23, 2011 when shares fell for seven straight days, dropping 9.5% (-$6.71) over that span.

Balance Sheet Analysis: The company’s current ratio of assets to liabilities came in at 1.93 last quarter. The current ratio is an indication of a firm’s liquidity and ability to meet creditor demands and generally, for every dollar the company owes in the short term, it has that figure available in assets that can be converted to cash in the short term.

Analyst Ratings: With 11 analysts rating the stock a buy, one rating it a sell and six rating the stock a hold, there are indications of a bullish stance by analysts.

(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)

Don’t Miss These Additional Hot Stories:

HEALTHY Drug Stocks Offering a Prescription for Stock Market PAIN>>

Will Europe Provide the Final Catalyst for Gold and Silver?

Is Microsoft Being SNEAKY?